Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P23/00—Anaesthetics
  • A61P23/02—Local anaesthetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Definitions

• the invention relates to methods of treating non-neuropathic pain. Specifically, the invention relates to methods of treating non-neuropathic pain by topically administering a local anesthetic, such as lidocaine, in an effective amount near the pain location. Most specifically, the invention relates to methods of treating non-neuropathic pain by administering a topical lidocaine patch to a patient, where the transdermal drug delivery results in no clinically meaningful serum drug levels nor produces anesthesia at the site of delivery, i.e. analgesia without anesthesia.
• a local anesthetic such as lidocaine
• Analgesics Pain can be treated with either analgesics or anesthetics.
• a distinguishing feature of analgesics is that they reduce the perception of pain without causing numbness or complete loss of sensation associated with anesthetics.
• opioids drugs that fall into only two classes of drugs: opioids and anti-inflammatories.
• Anesthetics fall into a different classification.
• Opioids work by mimicking the body's natural opioid- like substances, i.e. endorphins and enkaphalins, which are produced by the body to help alleviate pain. These substances, and the opioids, block pain by binding to the opioid receptors found throughout the central and peripheral nervous systems.
• Anti- inflammatories including NSAIDs and COX-2 inhibitors
• the FDA recognizes only these two classes as "general analgesics.”
• Pain falls into two broad categories: neuropathic pain and non-neuropathic pain.
• the methods associated with treating one type of pain are not necessarily effective at treating the other.
• Neuropathic pain is a particular type of pain that has a complex and variable etiology, distinct from nociceptive or inflammatory pain. It is generally a chronic condition attributable to complete or partial transection of a nerve or trauma to a nerve plexus, whereas non-neuropathic pain, i.e. nociceptive or inflammatory pain, occurs in the setting of a normal undamaged nervous system.
• Neuropathic pain is characterized by hyperesthesia (enhanced sensitivity to a natural stimulus), hyperalgesia (abnormal sensitivity to pain), allodynia (widespread tenderness, characterized by hypersensitivity to nonnoxious tactile stimuli), and/or spontaneous burning pain.
• hyperesthesia enhanced sensitivity to a natural stimulus
• hyperalgesia abnormal sensitivity to pain
• allodynia widespread tenderness, characterized by hypersensitivity to nonnoxious tactile stimuli
• spontaneous burning pain In humans, neuropathic pain tends to be chronic and may be debilitating. Non-neuropathic pain is just as complex and variable. Non-neuropathic pain includes common conditions such as arthritis pains, musculoskeletal pains, postoperative pains, and fibromyalgia.
• the invention revolves around the proposition that all pain, neuropathic or otherwise, is transmitted by specialized nerve fibers called "nociceptors.”
• the normal undamaged nociceptor nerve is only physiologically active and gives a normal discharge (resulting in the perception of pain) when the area of skin it innervates is injured by burn, cut, or bruise. This discharge is a normal function of the nerve. Otherwise, the nerve is silent and no pain is perceived in this region of the body.
• nociceptor peripheral nerve itself is damaged, i.e. neuropathic pain
• abnormal sodium channels develop at the site of nerve damage, resulting in (1) ectopic abnormal discharges in the normally silent nociceptor nerve, which causes (2) the development of a pain signal in the nociceptor even though no skin damage has occurred, and hence (3) the perception of abnormal spontaneous neuropathic pain and its accompanying hyperalgesia, hyperasthesia, and allodynia in the skin region it innervates. This is not normal function or discharge.
• abnormal sodium channels on the damaged nociceptor nerve have an extremely high affinity for sodium and sodium channel antagonist drugs
• extremely low doses of sodium channel blocking drugs delivered by intravenous route, oral route, or topical route can bind to these abnormal sodium channels, reduce the frequency of these abnormal discharges, and thus result in the alleviation of neuropathic pain without the complete blockage of the nerve's transmission and without sensory loss or motor blockade.
• non-neuropathic pain because the nervous system, including the nociceptor nerve, is not damaged, it has been believed that these abnormal sodium channels do not develop and the pain is solely a result of the inflammatory process.
• treatment of normally firing, undamaged nerves by such low doses of sodium channel blocking drugs has not been used or even contemplated.
• Non- neuropathic pains have not been treated with very low dose sodium channel blocking agents, delivered by any route.
• non-neuropathic pains usually have been treated by NSAIDs and COX-2 drugs, that directly interfere with the inflammatory process.
• anesthetics are usually injected directly into either the skin or the nerves in the region.
• anesthesia is not usually the optimal pain treatment as it renders the patient with a numb body part and, at times, paralysis of the involved body region.
• Lidocaine a well-known topical anesthetic
• has been used with success to treat pain associated with nerve injury i.e. neuropathic pain.
• lidocaine is an anesthetic whose sole mechanism of action is peripheral sodium channel antagonism
• its use as an analgesic without anesthesia in treating non-neuropathic pain has, heretofore, gone unexplored.
• It is surprising and unexpected that such a powerful anesthetic useful in treating neuropathic pain is effective to produce analgesia when treating pain where nerve injury is known not to have occurred.
• pathophysiologic events associated with non-neuropathic pain must also, like neuropathic pain, involve the production of high affinity sodium channels in the painful regions' uninjured nociceptor nerves.
• lidocaine as an analgesic without anesthesia in treating non-neuropathic pain can be a useful treatment where traditional analgesics and anesthetics might otherwise be used.
• a method including topically administering an effective amount of a local anesthetic, such as but not limited to lidocaine, to a patient is disclosed.
• the method is effective for inducing analgesia without anesthesia for treating non-neuropathic pain.
• Non-neuropathic pain suitable for treatment according to the invention includes pain associated with sprains; strains; soft-tissue injury (bruises and the like); repetitive motion injury; carpal tunnel syndrome; injury to tendons, ligaments, and/or muscles; conditions such as fibromyalgia, bursitis, castrochondritis, myofascial pain, and pain associated with arthritis, inflammation, contusions, post-surgical pain, and nociceptive pain.
• the local anesthetic, such as lidocaine is applied via a transdermal patch applied on or adjacent to the locus of pain.
• a topical local anesthetic drug such as but not limited to lidocaine
• This surprising and unexpected discovery has significance in the clinical setting and in the understanding of pathophysiological pain mechanisms.
• topical anesthetics which may be used include benzocaine, prilocaine, lidocaine, dubicaine, mepivacaine, bupivacaine, etc.
• a sodium channel antagonist drug such as lidocaine
• a sodium channel antagonist drug such as lidocaine
• Non-limiting examples of soft-tissue injuries include injury to the tendons, ligaments, muscles or bursa, and sprains and strains, etc. These, and other injuries, if occurring during a participation sport may be referred to as sports injuries. However, it makes no difference how the injury was received. The methods herein are effective in treating a broad range of such injuries. Other types of pain resulting from contusions, inflammation, bursitis, costrochondritis, and myofascial pains may also be treated. Other conditions, such as osteoarthritis, rheumatoid arthritis, fibromyalgia and carpal tunnel syndrome, that result in nociceptive pain can also be treated according to the invention.
• Fibromyalgia is a condition that is not easily diagnosed or treated. It is poorly understood with no agreed-upon underlying cause or pathophysiological mechanism. Many authorities believe it is caused by a disorder in the nervous system. Fibromyalgia is often associated with flu-like symptoms, including general body pain, coupled with points of sensitivity ("tender points") and pain at specific locations on the body. Despite the difficulty of treating this condition, treatment according to the method of the present invention can reduce the sensation/perception of pain associated with the condition without the development of anesthesia at the site of pain alleviation.
• a transdermal patch containing 5% lidocaine is applied to the skin at or near the locus of pain.
• the patch may contain other pharmaceutically active ingredients, as is known in the art, or other ingredients to help transdermal migration of the active ingredient, stability of the patch, adhesion and other concerns.
• LIDODERM lidocaine patch available from Endo Pharmaceuticals, Inc. Varying the size of the patch used varies the dosage. Often a patch is cut and only a portion is used. In some instances, the use of more than one patch may be advisable. Optimal pain relief often occurs when lidocaine patches are applied directly to the skin overlying the entire painful body region.
• LIDODERM (lidocaine patch 5%) is comprised of an adhesive material containing 5% lidocaine, which is applied to a non- woven polyester felt backing and covered with a polyethylene terephthalate (PET) film release liner. The release liner is removed prior to application to the skin. The size of the patch is 10 cm x 14 cm.
• Lidocaine is chemically designated as acetamide, 2-(diethylamino)-N-(2,6- dimethylphenyl), has an octanokwater partition ratio of 43 at pH 7.4, and has the following structure:
• Each adhesive patch contains 700 mg of lidocaine (50 mg per gram adhesive) in an aqueous base. It also contains the following inactive ingredients: dihydroxyaluminum aminoacetate, disodium edetate, gelatin, glycerin, kaolin, methylparaben, polyacrylic acid, polyvinyl alcohol, propylene glycol, propylparaben, sodium carboxymethylcellulose, sodium polyacryslate, D-sorbitol, tartaric acid, and urea.
• Another embodiment includes administering a transdermal patch to the patient at the locus of pain where the patch contains approximately 5% lidocaine as the only active ingredient. The remainder of the patch consists of inactive pharmaceutically acceptable agents.
• Inactive agents do not, in and of themselves, relieve pain. Those skilled in the art will recognize the importance of these inactive agents which facilitate transfer of the lidocaine through the patch and skin, aid in forming the patch itself, or address other concerns and needs. Again, the dosage may be varied by varying the size of the patch.
• transdermal patch is preferred because the application and release of lidocaine can be controlled through known techniques.
• topical application of a composition including gels, salves, and ointments containing lidocaine will suffice.
• Topical application of such a composition in effective amounts, will reduce the sensation/perception of pain in the local area.
• the amount of lidocaine or other anesthetic used will vary depending upon the efficiency of the delivery system. Directly applied gels, salves, ointments, etc. may require lesser amounts of the local anesthetic.
• lidocaine results in alleviation of pain (analgesia) without numbness or complete loss of sensation (anesthesia) or paralysis. This ability to alleviate pain without numbness or paralysis allows the patient, in many cases, to participate in many daily activities without being burdened by pain or numbness.
• topical lidocaine administration provides uniformity of treatment between patients since the drug is not subject to absorption through the digestive tract. This also reduces the likelihood of drug interactions and virtually eliminates the possibility of gastro-intestinal distress associated with NSAIDs and with opioids. This treatment is particularly effective for strains, sprains, arthritis pains, and post-operative local surgical pain since the analgesic acts locally. Further benefits include the lack of drug-drug interactions as no clinically meaningful plasma levels develops even with chronic usage.
• Lidoderm Topical lidocaine patch
• a 39 year old female was suffering from pain and severe discomfort from itching on her arms due to poison oak. She applied lidocaine patches to the painful and itching skin region. Within 30 minutes she began to report relief of the pain and itching directly underlying the site of patch application. Within 1.5 hours she reported nearly complete pain and itching relief.

Landscapes

• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pain & Pain Management (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Dermatology (AREA)
• Anesthesiology (AREA)
• Rheumatology (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (2)

Family

ID=21937331

Family Applications (1)

Country Status (6)

Cited By (6)

Families Citing this family (30)

Family Cites Families (83)

• 2001
  • 2001-10-25 US US10/045,341 patent/US20030124174A1/en not_active Abandoned
• 2002
  • 2002-10-23 JP JP2003537569A patent/JP2005506995A/ja not_active Withdrawn
  • 2002-10-23 EP EP02784262A patent/EP1446087A4/en not_active Withdrawn
  • 2002-10-23 CN CN028206193A patent/CN1571656B/zh not_active Expired - Fee Related
  • 2002-10-23 CA CA2464067A patent/CA2464067C/en not_active Expired - Fee Related
  • 2002-10-23 WO PCT/US2002/034077 patent/WO2003035000A2/en not_active Ceased
• 2006
  • 2006-01-20 US US11/336,001 patent/US20060147510A1/en not_active Abandoned
• 2009
  • 2009-12-17 JP JP2009286980A patent/JP2010065059A/ja active Pending
• 2010
  • 2010-05-28 JP JP2010122735A patent/JP2010202663A/ja active Pending

Also Published As

Similar Documents

Legal Events